Versión de HTML Básico
26
Juan Alberto Lancina Martín
Síndrome metabólico y litiasis urinaria de ácido úrico
40. Pak CY, Sakhaee K, Moe O et al. Biochemical profile of stone-
forming patients with diabetes mellitus. Urology. 2003; 61: 523-7.
41. Abate N, Chandalla M, Cabo-Chan AV, Moe OW, Sakhaee K. The
metabolic syndrome and uric acid nephrolithiasis: novel features of renal
manifestations of insulin resistance. Kidney Int. 2004; 65:386-92.
42. Cameron MA, Maalouf NM, Adams-Huet B, Moe OW, Sakhaee
K. Urine composition in type 2 diabetes: predisposition to uric acid ne-
phrolithiasis. J Am Soc Nephrol. 2006; 17: 1422-8.
43. Eisner BH, Porten SP, Bechis SK, Stoller ML. Diabetic kidney sto-
ne formers excrete more oxalate and have lower urine pH tha nondiabetic
stone formers. J Urol. 2010; 183: 2244-8.
44. Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Metabolic ba-
sis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol. 2010; 5:
1277-81.
45. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak
CY. Association of urinary pH with body weight in nephrolithiasis. Kidney
Int. 2004; 65:1422-5.
46. Siener R, Glatz S, Nicolay C, Hesse A. The role of overweight and
obesity in calcium oxalate stone formation. Obes Res 2004; 12: 106-13.
47. Negri AL, Spivacow FR, Del Valle EE, Forrester M, Rosende F,
Pinduli I. Role of overweight and obesity on the urinary excretion of pro-
moters and inhibitors of stone formation in stone formers. Urol Res. 2008;
36: 303-7.
48. Wrobel BM, Schubert G, Hörmann M, Strohmaier WL.
Overweight and obesity: risk factors in calcium oxalate stone disease?.
Avd Urol. doi: 10.1155/2012/438707.
49. Ekeruo WO, Tan YH, Young MD et al. Metabolic risk factors an
the impact of medical therapy on the management of nephrolithiasis in
obese patients. J Urol. 2004; 172: 159-63.
50. Lemann J, Pleuss JA, Worcester EM et al. Urinary oxalate increa-
ses with body size and diseases with increasing dietary calcium intake
among healthy adults. Kidney Int. 1996; 49: 200-8.
51. Taylor EN, Curhan GC. Body size and 24-hour urine composition.
Am J Kidney Dis. 2006; 48: 905-15.
52. Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee
K. Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc
Nephrol. 2007; 2: 883-8.
53. Rendina D, De Filippo G, Zampa G, Muscariello R, Mossetti G,
Strazzullo, P. Characteristic clinical and biochemical profile of recurrent
calcium-oxalate nephrolithiasis in patients with metabolic syndrome. Ne-
phrol Dial Transplant. 2011; 26: 2256-63
54. Sakhaee K, Capolongo G, Maalouf NM et al. Metabolic syndro-
me and the risk of calcium stones. Nephrol Dial Transplant. 2012; 27:
3201-9.
55. Cupisti A, Morelli E, Meola M, Cozza V, Parrucci M, Barsotti G.
Hypertension in kidney stone patients. Nephron. 1996; 73: 569-72.
56. Daudon M, Traxer O, Conort P, Lacour B, Jungers P. Type 2 dia-
betes increases the risk for uric acid stones. J Am Soc Nephrol. 2006; 17:
2026-33.
57. Daudon M, Lacour B, Jungers P. Influence of body size on urinary
stone composition in men and women. Urol Res. 2006; 34: 193-9.
58. Cho ST, Jung SI, Myung SC, Kim TH. Correlation of metabolic
syndrome with urinary stone composition. Int J Urol. 2013; 20: 208-13.
59. Sakhaee K, Maalouf NM: Metabolic syndrome and uric acid ne-
phrolithiasis. Semin Nephrol. 2008; 28: 174-80.
60. Chobanian MC, Hammerman MR. Insulin stimulates ammonia-
genesis in canine renal proximal tubular segments. Am J Physiol. 1987;
253: F1171-7.
61. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic
syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Ne-
phrol. 2007; 2: 550-6.
62. Bobulescu IA, Dubree M, Zhang J, McLeroy P, Moe OW. Effect of
renal lipid accumulation on proximal tubule Na+/H+ exhance and ammo-
nium secretion. Am J Physiol Renal Physiol. 2008; 294: F1315-22.
63. Vinay P, Lemieux G, Cartier P, Ahmad M. Effect of fatty acids on
renal ammoniogenesis in in vivo and in vitro studies. Am J Physiol. 1976;
231: 880-7.
64. Strohmaier WL, Wrobel BM, Schubert G. Overweight, insulin
resistance and blood pressure (parameters of the metabolic syndrome) in
uric acid urolithiasis. Urol Res. 2012; 40: 171-5.
65. Cheung BM, Li C. Diabetes and hypertension: is there a common
metabolic pathway?. Curr Atheroscler Rep. 2012; 14: 160-6.
66. Huang HS, Ma MC, Chen CF, Chen J. Lipid peroxidation and its
correlation with urinary levels of oxalate, citric acid and osteopontin in
patients with renal calcium oxalate stones. Urology. 2003; 62: 1123-8.
67. Khan SR. Is oxidative stress, a link between nephrolithiasis and
obesity, hypertension, diabetes, chronic kidney disease, metabolic syn-
drome?. Urol Res. 2012; 40: 95-112.
68. Tobili JE, Ferder L, Stella I, De Cavanaugh EM, Angerosa M, In-
serra F. Effects fo angiotensin II subtype I receptor blockade by losartan
on tubulo intestitial lesions caused by hyperoxaluria. J Urol. 2002; 168:
1550-5.
69. Tsao KC, Wu TL, Chang PY, Sun CF, Wu LL, Wu JT. Multiple risk
markers for atherogenesis associated with chronic inflamation are detec-
table in patients with renal stones. J Clin Lab Anal. 2007; 21: 426-31.
70. Taylor EN, Fung TT, Curhan CG. DASH-style diet associates with
reduced risk for kidney stones. J Am Soc Nephrol. 2009; 20: 2253-9.